Brief: Actinium Says Difference Of 5X For Iomab-B Vs Control Arm In The Number Of Patients Potentially Evaluable For Primary Endpoint Of Phase 3 Sierra Trial

Actinium Pharmaceuticals

13/12/2021 14:44

Dec 13 (Reuters) - Actinium Pharmaceuticals Inc  ATNM.A :
    * ACTINIUM PHARMACEUTICALS, INC. ANNOUNCES GREATER
DIFFERENCE OF
APPROXIMATELY 5X FOR IOMAB-B VERSUS CONTROL ARM IN THE NUMBER OF
PATIENTS POTENTIALLY EVALUABLE FOR THE PRIMARY ENDPOINT OF THE
PIVOTAL PHASE 3 SIERRA TRIAL AT THE 63RD ASH ANNUAL MEETING
    * ACTINIUM PHARMACEUTICALS- CONSISTENT 5-TIMES GREATER
DIFFERENCE
BETWEEN IOMAB-B VERSUS CONTROL ARM AT EACH 100-DAY NR-TRM
INTERIM ANALYSIS OF SIERRA TRIAL
    * ACTINIUM PHARMACEUTICALS INC - CONTROL ARM THERAPIES
FAILED TO
ACHIEVE A REMISSION IN 83% OF PATIENTS
    * ACTINIUM PHARMACEUTICALS INC - UNMET NEED IN RELAPSED AND
REFRACTORY AML DEMONSTRATED BY 66% OF PATIENTS ENROLLED IN
SIERRA
    * ACTINIUM PHARMACEUTICALS - SIGNIFICANTLY LOWER RATE OF
SEPSIS,
FEBRILE NEUTROPENIA IN PATIENTS RECEIVING IOMAB-B COMPARED TO
SALVAGE THERAPY

Source text for Eikon:  ID:nPncdQ92Da 
Further company coverage:  ATNM.A 

 ((Reuters.Briefs@thomsonreuters.com;))